Womens Health Club Womens Health Club
Abnormal Uterine Bleeding
Abortion
Acne Vulgaris
Acute Coronary Syndromes
Alopecia
Alzheimer's Disease
Amenorrhea
Anorexia Nervosa
Antiphospholipid Antibody Syndrome
Anxiety Disorder Generalized
Bipolar Disorder
Breast Cancer
Bulimia Nervosa
Carpal Tunnel Syndrome
Cataract
Cervical Cancer
Chlamydia
Cholelithiasis
Chronic Fatigue Syndrome
Colorectal Cancer
Cytomegalovirus
Depression
Diabetes Mellitus
Dysfunctional
Uterine Bleeding
Dysmenorrhea
Dysuria
Ectopic Pregnancy
Endometriosis
Eye Stye
Fibromyalgia
Syndrome
Genital Herpes
Genital Warts
Gonorrhea
Herpes Zoster
Hirsutism
HIV & AIDS
Hyperparathyroidism
Hypertension
Hyperthyroidism
Hypothyroidism
Infertility
Irritable Bowel
Syndrome
Kyphosis
Melasma
Menopause
Migraine Headache
Multiple Sclerosis
Myasthenia Gravis
Obsessive
Compulsive Disorder
Osteoarthritis
Osteoporosis
Panic Disorder
Pelvic Inflammatory Disease
Pelvic Pain
Psoriasis
Rosacea
Sarcoidosis
Scleroderma
Sjogren's Syndrome
Squamous Cell Carcinoma
Stroke
Syphilis
Systemic Lupus Erythematosus
Toxic Shock Syndrome
Urinary & Stress Incontinence
Urinary Tract Infection
Uterine Cancer
Uterine Leiomyomas
Uterine Prolapse
Vaginal Cancer


HIV and AIDS

The Centers for Disease Control and Prevention (CDC) first recognized human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) in 1981. One of the most widely publicized diseases, AIDS is characterized by progressive immunodeficiency. Although it's characterized by progressive destruction of cell-mediated (I-cell) immunity, it also affects humoral immunity, and even autoimmunity because of the central role of CD4 + T cells in immune reactions. The resultant immunodeficiency makes the patient susceptible to opportunistic infections, unusual cancers, and other abnormalities that define AIDS.

A retrovirus - my, type I - is the primary etiologic agent. Transmission of HIV occurs by contact with infected blood or body fluids and is associated with identifiable high-risk behaviors. As a result, HIV incidence is disproportionately high in I. V. drug users, homosexual and bisexual men, neonates of HIV-infected women, recipients of contaminated blood or blood products (dramatically decreased since the mid-1980s), and heterosexual partners of people in the former groups. Because of similar routes of transmission, AIDS shares epidemiologic patterns with hepatitis B and sexually transmitted diseases. Thus, the number of women with HIV and AIDS is rising steadily, and HIV infection is now the third leading cause of death among women ages 25 to 44. HIV and AIDS also disproportionately affect minority women in the United States, making them the leading cause of death among Black women in this age group and Hispanic women in general. These two minority groups account for over 80% of women affected with HIV ANd AIDS in the United States. Also, because women in general have poorer access to or fail to use health care and social services, HIV-infected women are one third more likely to die sooner than HIV-infected men.

The natural history of AIDS infection begins with infection by the HIV retrovirus, which is detectable only by laboratory tests, and ends with the severely immunocompromised, terminal stage of this disease. Depending on individual variations and the presence of cofactors that influence progression, the time elapsed from acute HIV infection to the appearance of symptoms (mild to severe), to diagnosis of AIDS and, eventually, to death varies greatly. More recently, dramatic advances in antiretroviral therapy and treatment and prophylaxis of common opportunistic infections have delayed the natural progression of HIV infection and prolonged survival.

What causes HIV and AIDS ?

AIDS results from infection with HIV, which strikes cells bearing the CD4 antigen; the latter (normally a receptor for major histocompatibility complex molecules) serves as a receptor for the retrovirus and lets it enter the cell. HIV prefers to infect the CD4 + lymphocyte but may also infect other CD4 + antigen-bearing cells in the GI tract and uterine cervix as well as neuroglial cells. Mter invading a cell, the HIV replicates, leading to cell death, or becomes latent. HIV infection leads to profound pathology either directly,through destruction of CD4 + cells, other immune cells, and neuroglial cells, or indirectly, through the secondary effects of CD4 + T-cell dysfunction and resultant immunosuppression.The infection process takes three forms:

  • immunodeficiency (opportunistic infections and unusual cancers)
  • autoimmunity (lymphoid interstitial pneumonitis, arthritis, hypergammaglobulinemia, and production of autoimmune antibodies)
  • neurologic dysfunction (AIDS dementia complex, HIV encephalopathy, and peripheral neuropathies).HIV is transmitted by direct inoculation during intimate sexual contact, especially associated with the mucosal trauma of receptive rectal intercourse, transfusion of contaminated blood or blood products (a risk diminished by routine testing of all blood products), sharing of contaminated needles, or transplacental or postpartum transmission from infected mother to fetus (by cervical or blood contact at delivery and in breast milk). For women, transmission through heterosexual intimate contact is the leading cause of transmission. Accumulating evidence suggests that casual household or social contact doesn't transmit HIY. The average time between exposure to the virus and diagnosis of AIDS is 8 to 10 years, but shorter and longer incubation times have also been recorded.

Signs and symptoms of HIV and AIDS

HIV infection manifests in many ways. after a high-risk exposure and inoculation, the infected person usually experiences a mononucleosis-like syndrome, which may be attributed to the flu or another virus. The patient then may remain asymptomatic for years. In this latent stage, the only sign of HIV infection is laboratory evidence of seroconversion. When symptoms appear, they may take many forms, such as persistent generalized adenopathy, nonspecific signs and symptoms (weight loss, fatigue, night sweats, and fevers), neurologic symptoms resulting from HIV encephalopathy, an opportunistic infection, or cancer.

In addition to the symptoms common to men and women, women also experience HIV-gynecologic problems, such as recurrent vaginal yeast infections, other vaginal infections, severe herpes simplex virus ulcers, idiopathic genital ulcers, human papillomavirus infections, pelvic inflammatory disease, and menstrual irregularities.

The clinical course of HIV and AIDS varies slightly in children. Apparently, incubation time is shorter, with a mean of 17 months. Signs and symptoms resemble those in adults, except for findings related to sexually transmitted disease. Children show virtually all of the opportunistic infections observed in adults, with a higher incidence of bacterial infections, including otitis media, pneumonias other than that caused by Pneumocystis carinii, sepsis, chronic salivary gland enlargement, and lymphoid interstitial pneumonia.

Diagnosis information

The CDC defines AIDS as an illness characterized by one or more "indicator" diseases that coexist with laboratory evidence of HIV infection and other possible causes of immunosuppression. The CDC's current AIDS surveillance case definition requires laboratory confirmation of HIV infection in people who have a CD4+ T-lymphocyte count of greater than 200 cells/ul or who have an associated clinical condition or disease.

The most commonly performed tests, antibody tests, indicate HIV infection indirectly by revealing HIV antibodies. The recommended protocol requires initial screening of individuals and blood products with an enzyme linked immunosorbent assay (EliS A). A positive EliSA should be repeated and then confirmed by an alternate method, usually the Western blot or an immunofluorescence assay. The radioimmunoprecipitation assay is considered more sensitive and specific than the Western blot. Because it requires radioactive materials, it's a poor choice for routine screening. In addition, antibody testing isn't reliable. Because people produce detectable levels of antibodies at different rates a "window" varying from a few weeks to as long as 3S months in one documented case - an HIV. infected person can test negative for HIV antibodies. Antibody tests are also unreliable in neonates because transferred maternal antibodies persist for 6 to 10 months; To overcome these problems, direct tests are used, including antigen tests, HIV cultures, nucleic acid probes of peripheral blood lymphocytes, and the polymerase chain reaction.

Additional tests to support an HIV diagnosis and help evaluate the severity of immunosuppression include CD4 + and CD8+ T-lymphocyte subset counts, erythrocyte sedimentation rate, complete blood cell count, serum beta2-microglobulin, p24 antigen, neopterin levels, and energy testing. Because many opportunistic infections in AIDS patients are reactivations of previous infections, patients are also tested for syphilis, hepatitis B, tuberculosis, toxoplasmosis and, in some areas, histoplasmosis.

Treatment of HIV and AIDS

To date, there's no known cure for AIDS; however, in 1998, the CDC recommended that all people who have symptomatic or HIV infection receive aggressive antiviral therapy. In July of 2003, the CDC revised its guidelines for initiating treatment of antiretroviral therapy. (See New guidelines for antiretroviral therapy.

Treatment for HIV infection can be divided into four categories: prevention and therapy for opportunistic infections and malignancies, antiretroviral treatment, and hematopoietic stimulating factors.

Nucleoside analogues (sometimes called reverse transcriptase inhibitors) have been the mainstay of AIDS therapy in recent years. These drugs, which include zidovudine (AZT), lamivudine, didanosine, stavudine, abacavir, and zaldtabine, interfere with viral reverse transcriptase, which impairs HIV's ability to turn its ribonucleic add into deoxyribonucleic add for insertion into the host cell.

Antiretroviral therapy typically begins when the patient's CD4+ T-cell count drops to less than 350/ul or when the patient develops an opportunistic infection. Most clinidans recommend starting the patient on a combination of these drugs in an attempt to gain the maximum benefit and inhibit the production of resistant mutant strains of HIV. The drug combinations and dosages are then altered, depending on the patient's response.

Increasingly, physicians are basing changes in therapy on the patient's viral load rather than on her CD4+T cell count. Because the CD4 + count is influenced by the total white blood cell count changes in the CD4 + count may have nothing to do with changes in the patient's HIV status. Many physicians recommend that a patient on antiretroviral therapy should have her viral load checked every 3 months.

Protease inhibitors. another class of antiretroviral agents, have greatly increased the life expectancy of AIDS patients. These drugs (which include ritonavir, indinavir, nelfinavir, and saquinavir) block the enzyme protease, which HIV needs to produce virions, the viral particles that spread the virus to other cells. The use of protease inhibitors dramatically reduces viral load - sometimes to undetectable levels - while producing a corresponding increase in the CD4 + T.cell COunt and, because they act at a different site than nucleoside analogues, protease inhibitors don't produce additional adverse effects when added to a patient's regimen.

After antiviral therapy is initiated, treatment should be aggressive. Initially, highly active antiviral therapy, consisting of a triple drug therapy regimen - a protease inhibitor and two non-nucleoside reverse transcriptase inhibitors - is recommended. In addition to these primary treatments,anti-infective's are used to combat opportunistic infections (or, with some patients, prophylactically to help resist opportunistic infections), and antineoplastic drugs are used to fight associated neoplasms. Supportive treatments help maintain nutritional status and relieve pain and other distressing physical and psychological symptoms.

Special considerations or prevention

Advise health care workers and the public to use precautions in all situations that risk exposure to blood, body fluids, and secretions. Diligently practicing standard precautions can prevent the inadvertent transmission of AIDS and other infectious diseases transmitted by similar routes.

  • Recognize that a diagnosis of AIDS is profoundly distressing because of the disease's social impact and discouraging prognosis. The patient may lose her job and financial security as well as the support of family and friends. Do your best to help the patient cope with an altered body image, the emotional burden of serious illness, and the threat of death, and encourage and assist the patient in learning about AIDS societies and support programs.
  • Encourage HIV-positive women to have a complete gynecologic evaluation, including a Papanicolaou smear initially, during prenatal care, and then annually (every 6 months for those who are symptomatic).
  • Always use a condom (latex, not sheepskin) and spennicide (spermicide kills HIV) for any sexual contact. If you use a lubricant with a latex condom, use only a water-based lubricant such as K- Y jelly. Do not use petroleum jelly (Vaseline), vegetable shortening (Crisco), hand lotion, or baby oil, as these substances can break down latex in a matter of minutes. Be aware, however, that even the proper use of a condom is not a guarantee against the transmission of HIV.
  • Food poisoning can be very dangerous for people with HIV or AIDS infection.


Bookmark and Share

|| Home || Contact Us ||


Disclaimer: Womens-health-club.com website is designed for educational purposes only. It is not intended to treat, diagnose, cure, or prevent any disease. Always take the advice of professional health care for specific medical advice, diagnoses, and treatment. We will not be liable for any complications, or other medical accidents arising from the use of any information on this web site.